Medical Tidbits, Data presented at ObesityWeek showed Saxenda® treatment demonstrated significant and sustained weight loss over three years compared with placebo

overweight man exhausted in gym

Los Angeles, US, 4 November 2015 Today, new data from the phase 3a SCALE(TM) (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and Prediabetes three-year trial extension were presented at ObesityWeek 2015, the 3rd annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society. The extension part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline), demonstrated that treatment with Saxenda® (liraglutide 3 mg) in combination with a reduced-calorie diet and increased physical activity resulted in significant and sustained weight loss over the three-year span, compared with placebo (reduced-calorie diet and increased physical activity alone).

Data on Allergan’s Rapastinel and NRX-1074 (AGN-241660) presented at the Society for Neuroscience (SfN) Annual Meeting

DUBLIN, Nov. 4, 2015 /PRNewswire/ — Allergan plc. (NYSE: AGN), a leading global pharmaceutical company today announced that 6 poster presentations for two investigational medications Rapastinel (GLYX-13 and NRX-1074 were presented at the Society for Neuroscience (SfN) Annual Meeting in Chicago, October 17 – 21, 2015.  read more

Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting

THOUSAND OAKS, Calif., Nov. 4, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it will present key results from several studies related to Enbrel® (etanercept) and ABP 501, an adalimumab biosimilar candidate, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Francisco, Nov. 7-11, 2015. These data reinforce Amgen’s continued commitment to delivering high-quality medicines that may help to improve the lives of people with serious rheumatologic diseases. read more

GSK’s Nucala® (mepolizumab) receives approval from US FDA

 First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype

GlaxoSmithKline plc (LSE/NYSE: GSK) today received approval from the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for Nucala® (mepolizumab) as an add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Nucala is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.  read more

World’s First Endovascular Neuromodulation Device Implanted in Man for the Treatment of Congestive Heart Failure  

Enopace Biomedical, a developer of minimally invasive, implantable endovascular neuromodulation therapy for heart failure patients, announced today the first successful human implantation of its Harmony™ System, a catheter-based neurostimulator device to treat patients with congestive heart failure.

Virttu Biologics Shows Robust Evidence Of Immunological Activity In Mesothelioma Patients Following SEPREHVIR® Administration Results To Be Presented At Society For ImmunoTherapy Of Cancer (SITC)  

GLASGOW, United Kingdom, Nov. 5, 2015 /PRNewswire/ — Virttu Biologics, a clinical stage oncolytic immunotherapeutic company developing SEPREHVIR, a tumor-targeted HSV, are pleased to announce the presentation of two posters at SITC’s 30th Anniversary Annual Meeting  on November 4th-8th. Abstracts were published in the Journal for ImmunoTherapy of Cancer, Nov 4th 2015 read more

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer

Merck KGaA, Darmstadt, Germany, and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanced NSCLC setting. The study, JAVELIN Lung 100, is designed to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who have not previously received any treatment for their systemic lung cancer. Avelumab (previously known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer. read more

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.